https://orcid.org/0000-0002-5979-5835
References
- Wong QYA, Chew FT. Defining skin aging and its risk factors: a systematic review and meta-analysis. Sci Rep. 2021;11(1):22075. doi:10.1038/s41598-021-01573-z
- Charles finn J, Cox SE, Earl ML. Social implications of hyperfunctional facial lines. Dermatol Surg. 2003;29(5):450–455. doi:10.1046/j.1524-4725.2003.29112.x
- Coleman S, Grover R. The anatomy of the aging face: volume loss and changes in 3-dimensional topography. Aesthet Surg J. 2006;26(1):S4–S9. doi:10.1016/j.asj.2005.09.012
- Dayan S, Yoelin SG, De Boulle K, Garcia JK. The psychological impacts of upper facial lines: a qualitative, patient-centered study. Aesthet Surg J Open Forum. 2019;1:2. doi:10.1093/asjof/ojz015
- Yi K-H, Lee J-H, Hu H-W, Kim H-J. Novel anatomical guidelines on botulinum neurotoxin injection for wrinkles in the nose region. Toxins. 2022;14:342. doi:10.3390/toxins14050342
- Yi KH, Lee JH, Hu HW, Kim HJ. Anatomical proposal for botulinum neurotoxin injection for glabellar frown lines. Toxins. 2022;14(4):268. PMID: 35448877; PMCID: PMC9032255. doi:10.3390/toxins14040268
- Wrinkles; 2022. Available from: https://my.clevelandclinic.org/health/articles/10984-wrinkles. Accessed January 26, 2023.
- Swift A, Liew S, Weinkle S, Garcia JK, Silberberg MB. The facial aging process from the “inside out”. Aesthet Surg J. 2021;41(10):1107–1119. PMID: 33325497; PMCID: PMC8438644. doi:10.1093/asj/sjaa339
- Cohen JL, Kaufman J, Peredo MI, Down R, Mashburn J. Assessment of psychological well-being after abobotulinumtoxina treatment: a comparison of 2 reconstitution volumes. Dermatol Surg. 2020;46(2):289–292. doi:10.1097/dss.0000000000001940
- Cosio T, Campione E. A new hypothesis in botulin therapy for depression: insula cortex modification. Dermatol Ther. 2019;32. doi:10.1111/dth.13008
- Lagueny A, Burbaud P. Mécanisme d’action, indication et résultats des traitements par la toxine botulinique [Mechanism of action, clinical indication and results of treatment of botulinum toxin]. Neurophysiol Clin. 1996. 26(4):216–226. French. PMID: 8975111. doi:10.1016/s0987-7053(96)85003-9
- Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200–235. doi:10.1124/pr.116.012658
- Solish N, Carruthers J, Kaufman J, et al. Overview of daxibotulinumtoxinA for injection: a novel formulation of botulinum toxin type A. Drugs. 2021;81:2091–2101. doi:10.1007/s40265-021-01631-w
- Kaufman-Janette J, Cox SE, Dayan S, Joseph J. Botulinum toxin type A for glabellar frown lines: what impact of higher doses on outcomes? Toxins. 2021;13(7):494. doi:10.3390/toxins13070494
- Field M, Splevins A, Picaut P, et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and incobotulinumtoxinA (Xeomin®) neurotoxin content and potential implications for duration of response in patients. Toxins. 2018;10(12):535. PMID: 30551641; PMCID: PMC6316182. doi:10.3390/toxins10120535
- Revance announces FDA approval of DAXXIFY™ (daxibotulinumtoxinA-lanm) for injection, the first and only peptide-formulated neuromodulator with long-lasting results; 2023. Available from: https://www.businesswire.com/news/home/20220908005320/en. Accessed: January 26, 2023.
- Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA in the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145:45–58.
- Fabi SG, Cohen JL, Green LJ. DaxibotulinumtoxinA for injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. Dermatol Surg. 2021;47(1):48–54. doi:10.1097/DSS.0000000000002531
- Malmirchegini R, Too P, Oliyai C, Joshi A. Revance’s novel peptide excipient, RTP004, and its role in stabilizing daxibotulinumtoxinA (DAXI) against aggregation. Toxicon. 2018;156:S72–3. doi:10.1016/j.toxicon.2018.11.174
- Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838–845. PMID: 31791824. doi:10.1016/j.jaad.2019.06.1313
- Glogau R, Kontis TC, Liu Y, Gallagher CJ. Progressive improvement in static glabellar lines after repeated treatment with daxibotulinumtoxinA for injection. Dermatol Surg. 2021;47(12):1579–1584. PMID: 34417396; PMCID: PMC8612903. doi:10.1097/DSS.0000000000003211
- Green JB, Mariwalla K, Coleman K, et al. A large, open-label, phase 3 safety study of daxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study. Dermatol Surg. 2021;47:42–46. doi:10.1097/DSS.0000000000002463